


CLAIMS


What is claimed is:

1. An immunoconjugate wherein a compound of the formula (I)



wherein X is Cl, Br, or tosylate ~~a nucleophilically displaceable leaving group~~, or a pharmaceutically acceptable salt thereof, is conjugated at the -NH₂ group thereof via a peptidyl linker to an antibody or an antigen binding fragment such antibody.

2. An immunoconjugate according to claim 1, having a structure according to formula (IIIa)



wherein

AA^a and each AA^b are independently selected from the group consisting of alanine, β-alanine, γ-aminobutyric acid, arginine, asparagine, aspartic acid, γ-carboxyglutamic acid, citrulline, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, norleucine, norvaline, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine;

m is 0, 1, 2, 3, 4, or 5;


Y is a spacer moiety;

n is 1, 2, 3, 4, or 5; and

Ab represents the antibody or antigen binding fragment thereof;

or a pharmaceutically acceptable salt thereof.

3. An immunoconjugate according to claim 1, having a structure according to formula (IIIa')




wherein

n is 1, 2, 3, 4, or 5; and

Ab represents the antibody or antigen binding fragment thereof;
or a pharmaceutically acceptable salt thereof.


4. An immunoconjugate according to claim 3, wherein the antibody is a human monoclonal antibody that recognizes a human antigen selected from the group consisting of CD70, mesothelin, PSMA, CD19, glypican-3, B7H4, RG-1, CD22, and PTK7.
5. A compound having a structure according to formula (II)




wherein

X is Cl, Br, or tosylate ~~a nucleophilically displaceable leaving group~~;

AA^a and each AA^b are independently selected from the group consisting of alanine, β -alanine, γ -aminobutyric acid, arginine, asparagine, aspartic acid, γ -carboxyglutamic acid, citrulline, cysteine, glutamic acid, glutamine, glycine, histidine, isoleucine, leucine, lysine, methionine, norleucine, norvaline, ornithine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine;




and



or a pharmaceutically acceptable salt thereof.

12. A compound according to formula (I)



wherein X is Cl, Br, or tosylate ~~a nucleophilically displaceable leaving group~~, or a pharmaceutically acceptable salt thereof.

13. Use of a therapeutically effective amount of an immunoconjugate having a structure according to claim 3 in the manufacture of a medicament for treating a cancer in a subject suffering from such cancer, wherein the cancer is renal cancer, pancreatic cancer, ovarian cancer, lymphoma, colon cancer, mesothelioma, gastric cancer, lung cancer, prostate cancer, adenocarcinoma, liver cancer, or breast cancer.

14. — ~~A use according to claim 13, wherein the cancer is renal cancer, pancreatic cancer, ovarian cancer, lymphoma, colon cancer, mesothelioma, gastric cancer, lung cancer, prostate cancer, adenocarcinoma, liver cancer, or breast cancer.~~

1514. A use according to claim 13, wherein the cancer is characterized by cancer cells that express human CD70, mesothelin, PSMA, CD19, glypican-3, B7H4, RG-1, CD22, or PTK7.
